DEVICE CIVIL PENALTY PROCESSING DELAYS GIVE FIRMS TIME TO MAKE CORRECTIONS, FDA TELLS REP. BARTON; LEXICOR GETS WAIVER DUE IN PART TO CORRECTIVE ACTIONS
This article was originally published in The Gray Sheet
Executive Summary
Device civil penalty processing delays by FDA can benefit companies by giving them time to take corrective actions that could deflect final imposition of the fines, FDA says in a recent letter to Rep. Joe Barton (R-Tex.) responding to the House Commerce/Oversight Subcommittee chairman's inquiry into the agency's civil money penalties program.
You may also be interested in...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.